Verastem Catapults To Mid-stage Development with Pfizer Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The Massachusetts-based cancer stem cell company has struck two deals in as many days in an effort to move compounds into the clinic for various types of cancers and multiple targets.
You may also be interested in...
Verastem Trumpets Early Clinical Results For FAK Program, Discloses Timelines And Plans
Addressing an audience of 150 attendees at its first clinical-stage R&D day on July 11, Verastem Inc. put forward its new senior executive team, as well as an eminent authority in cancer stem cell biology, to describe its clinical progress thus far, and its future plans.
Start-Up Quarterly Statistics, Q3 2012
In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.
Verastem Joins The Public Markets With A Strong IPO
Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.